Loading quotes...

Forecast

The analysts' average price target is €308.85 (+5.41%). The median is €313.68 (+7.06%).

Buy	26
Hold	9
Sell	0

News Go to news feed

Labcorp falls after disappointing investor day despite confirmed forecast

Labcorp shares fell about 4.3% on the day of the investor day to $307.43 after management confirmed the existing full-year forecast but delivered no upward revision. The CEO and CFO presented a multi-year growth framework: 2026 revenue forecast of $14.71–14.83 billion, annual revenue growth of 5–8% through 2029, and adjusted EPS growth of 8.5–11.5% (EPS range $18.10–18.55). Analyst consensus and a consensus price target of around $330 had already priced in positive expectations, so the event triggered profit-taking and the share decline in a weak US market environment. » More on de.investing.com
Labcorp confirms 2026 guidance and unveils growth target through 2029

Labcorp confirms its 2026 revenue guidance of $14.71–14.83 billion and expects adjusted earnings per share of $18.10–18.55 as well as free cash flow of $1.24–1.36 billion. Through 2029 the company is targeting average annual revenue growth of 5–8% and adjusted EPS growth of 8.5–11.5%, along with an increase in adjusted operating margin of 75–150 basis points. For 2026 Labcorp expects $11.45–11.53 billion in Diagnostics Laboratories and $3.27–3.30 billion in Biopharma Laboratory Services. Management cites technology leadership in specialty testing, partnerships with health systems and pharma, and the use of AI and robotics as strategic priorities. » More on de.investing.com
Labcorp acquires MLM Medical Labs, expands global central-lab network

Labcorp announced the acquisition of MLM Medical Labs; financial terms were not disclosed. The deal makes Labcorp the only provider with its own central-lab network on four continents and strengthens its presence in North America, Europe, Asia and Africa. MLM operates, among other facilities, Africa’s first fully CAP‑accredited central laboratory and complements Labcorp’s capacities for biomarker and specialty testing as well as multinational clinical trials. Evercore advised Labcorp on the financial side; Pierson Ferdinand and Hogan Lovells provided legal counsel. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, LABCORP HOLDINGS has already paid €1.86 in dividends. The last payout was in September.

Financials

In the last quarter, LABCORP HOLDINGS had revenue of €3.27bn and net profit of €261.72m

(EUR)	June 2026	YoY
Revenue	3.27bn	9.24%
Gross profit	974.35m	9.77%
Net profit	261.72m	29.67%
EBITDA	544.04m	20.51%

Fundamentals

Metric	Value
Market capitalization	€23.77bn
Number of shares	81.1m
52-week high/low	€304.59 - €217.90
Dividend yield	0.85%
Dividends TTM	€2.48
Beta	0.85
P/E ratio	27.03
PEG ratio	0.82
P/B ratio	3.12
P/S ratio	1.86

Company profile

Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.